Liver Transplantation Defines Long-Term Survival in HCC : Hepatol Commun | May 2026

Introduction

Hepatocellular Carcinoma remains one of the leading causes of cancer-related mortality worldwide. Although curative-intent therapies such as liver transplantation, surgical resection and ablation can achieve durable disease control, long-term survival remains limited by tumor recurrence, progressive cirrhosis and competing liver-related complications. Data defining predictors of true long-term survival beyond 10 years have remained scarce.

Problem Statement

Most HCC outcome studies focus on short- or intermediate-term survival, whereas determinants of ≥10-year survival are poorly characterized. In particular, the relative long-term impact of liver transplantation compared with resection or ablation in real-world populations requires further clarification.

Summary

This large National Cancer Database analysis evaluated nearly 250,000 patients diagnosed with HCC between 2004 and 2022 to identify factors associated with survival beyond 10 years. Long-term outcomes remained poor overall, with only 3.3% of patients achieving ≥10-year survival, emphasizing the aggressive biologic and cirrhotic burden associated with HCC.

Among all treatment modalities, Liver Transplantation emerged as the dominant determinant of long-term survival. Compared with ablation, liver transplantation increased the odds of surviving ≥10 years nearly twelvefold, substantially outperforming surgical resection and all non-curative therapies. Decision-tree analyses further confirmed transplantation as the single most important predictor of durable survival.

The superiority of transplantation likely reflects its unique ability to simultaneously eliminate both tumor burden and the underlying cirrhotic liver substrate responsible for de novo carcinogenesis and hepatic decompensation. In contrast, resection and ablation remove or destroy focal tumors while leaving the diseased liver in place, allowing continued risk for recurrence and liver-related mortality.

Surgical resection also significantly improved long-term survival compared with ablation, although the magnitude of benefit remained considerably lower than transplantation. Non-curative therapies were associated with substantially worse outcomes, underscoring the importance of early-stage diagnosis and access to definitive treatment strategies whenever feasible.

One of the most important findings was the persistence of racial disparities in transplant access and survival. Black patients demonstrated lower odds of receiving liver transplantation and correspondingly lower likelihood of ≥10-year survival. These observations reinforce longstanding concerns regarding inequities in transplant referral, waitlist access, socioeconomic barriers and healthcare delivery within HCC management pathways.

Clinically, the study reinforces that long-term cure in HCC depends not only on oncologic control but also on management of the underlying liver disease. The exceptional survival associated with transplantation highlights the central importance of careful candidate selection, surveillance-based early detection and equitable access to transplant evaluation.

The findings additionally support ongoing efforts to expand transplant eligibility through downstaging protocols, improved locoregional bridging therapies and optimized organ allocation systems. As systemic therapies improve and multidisciplinary HCC care evolves, transplantation may become increasingly integrated into broader biologic treatment algorithms rather than purely anatomy-based selection models.

Overall, this large national analysis demonstrates that liver transplantation provides the greatest likelihood of achieving ≥10-year survival in HCC, far surpassing other curative-intent therapies. The study also highlights persistent disparities in transplant access and emphasizes that equitable delivery of transplantation remains essential for improving long-term outcomes in hepatocellular carcinoma.